SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bonk is a dog-themed memecoin on the Solana blockchain, launched on Christmas Day 2022 to revitalize the Solana community following the FTX collapse. Created by an anonymous team of 22 Solana developers and builders, Bonk distributed 50% of its total 100 trillion token supply via airdrop to community members including NFT collectors, developers, and artists.   The project positions itself as "the first Solana dog coin for the people, by the people," explicitly rejecting venture capital backing in favor of grassroots community ownership. What sets Bonk apart from other memecoins is its combination of fair launch mechanics, extensive ecosystem integration, and active deflationary strategy.   Built on Solana, BONK benefits from fast transaction speeds and low fees that make it practical for everyday use. Native products include LetsBonk.fun (a memecoin launchpad that briefly became Solana's market leader in 2025, surpassing Pump.fun with over 78% market share), BonkSwap (a decentralized exchange) and BonkBot (a Telegram trading bot with built-in burn mechanics).   BONK is available across 10 blockchain networks and listed on major exchanges including Binance, Coinbase, Kraken, and Robinhood. Governance is handled by BonkDAO, which holds 15% of the token supply and makes decisions through on-chain voting.   The community has organized several major burn events, most notably the December 2024 BURNmas campaign that destroyed 1.69 trillion tokens worth over $50 million. In September 2025, Nasdaq-listed Safety Shot, Inc. formed BONK Holdings LLC and acquired over 2.5% of the circulating supply (valued at $55-63 million), making BONK one of the first memecoins to attract formal corporate treasury adoption. Core contributor Nom was appointed to Safety Shot's board, and the company holds a 10% revenue share in LetsBonk.fun.  As with all memecoins, BONK is a highly speculative asset with substantial volatility. Its value is primarily driven by community sentiment, social media momentum, and meme culture rather than traditional utility.   The anonymous team, while common in the memecoin space, means investors should exercise appropriate caution. Despite these risks, Bonk has established itself as one of the most successful community-driven tokens in the Solana ecosystem, approaching 1 million unique holders and expanding from a simple memecoin into meaningful DeFi infrastructure.

BONK

BONK attention is driven mainly by speculative calls for a memecoin rebound alongside chatter about a possible Bonk.fun relaunch, growing holder counts and token burns; these developments are discussed as expectations rather than confirmed catalysts. Traders are largely bullish and adding to positions, while others complain that BONK has lagged or quickly surrendered gains.

Shiba Inu (SHIB) is a decentralized, community-led cryptocurrency ecosystem built on the Ethereum blockchain. Originally launched as a meme-based project, it has evolved into a comprehensive financial ecosystem designed to offer a decentralized alternative to traditional banking. Its main value proposition lies in its transition from a social phenomenon into a functional utility network, supported by a vast global community known as the ShibArmy and a commitment to 100% community ownership with no central leadership.  The ecosystem features its own decentralized exchange, ShibaSwap, where users can trade, provide liquidity, and earn rewards. To address Ethereum’s high costs and slow speeds, the project utilizes Shibarium, a Layer 2 scaling solution that processes transactions faster and more affordably.  The project employs a unique three-token model to manage its economy and governance. SHIB serves as the primary currency for trading and payments, while LEASH offers scarcity-based incentives for dedicated supporters. BONE acts as the governance token, allowing holders to vote on proposals through the Doggy DAO and serving as the native gas token for the Shibarium network.

Shiba Inu

SHIB is drawing attention for choppy, mostly sideways trading, with traders repeatedly discussing consolidation and whether it can break resistance or resume a decline. Some are accumulating and anticipating a rebound, while others call the token stagnant and question its utility and prospects.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Promising early data for Lillys investigational ovarian-cancer drug Sofe-M is drawing pipeline interest, while traders also weigh oncology updates against expectations for the quarterly report and continued obesity-drug growth. The mood is mixed: bullish comments about Lillys business and pipeline sit alongside concerns about the share-price pullback and valuation.

Kratos Defense & Security Solutions, Inc. engages in the provision of mission critical products, services and solutions for United States national security priorities. It operates through the Kratos Government Solutions (KGS) and Unmanned Systems (US) segments. The KGS segment consists of an aggregation of KGS operating segments, including microwave electronic products, space, satellite and cyber, training solutions. The US segment refers to the unmanned aerial, unmanned ground, unmanned seaborne and related command, control and communications system businesses. The company was founded on December 19, 1994, and is headquartered in Round Rock, TX.

Kratos Defense & Security Solutions Inc

Kratos is drawing attention after a prolonged selloff brought shares near their 52-week lows, despite contract announcements, a sizable backlog and bullish analyst coverage. Traders are split between buying the dip ahead of the Q3 earnings report and warning that rich valuation, insider selling and questions about converting demand into profits could keep pressure on the stock.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

Disney is drawing attention as traders watch its recovery toward recent highs, citing bullish technical signals and positioning in calls ahead of the upcoming earnings report. Bulls see momentum continuing, while skeptics point to repeated resistance and the stocks history of struggling to sustain breakouts.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Lumentums AI data-center optics demandand CEO comments that key components are booked through early 2029underpin bullish discussion, alongside expectations for growth in optical networking. Traders are also debating valuation and capacity constraints as the stock and optical sector swing sharply, with some viewing the pullback as profit-taking and others warning that the crowded AI trade may be cooling.

Spotify Technology SA engages in the provision of digital music services. It operates through the Premium and Ad-Supported segments. The Premium segment provides subscribers with online and offline streaming access of music and podcasts on computers, tablets, and mobile devices. The Ad-Supported segment offers users with limited on-demand online access of music and unlimited online access of podcasts on computers, tablets, and mobile and smart devices. The company was founded by Daniel Ek and Martin Lorentzon on December 27, 2006 and is headquartered in Stockholm, Sweden.

Spotify Technology S.A.

Spotifys quarterly report and stronger-than-expected profit outlook are driving attention: traders point to premium subscriber growth, improving margins and faster ad growth as reasons for the sharp share gain, despite revenue and EPS misses. Others question the rally, citing rising expenses and weaker free cash flow.

The Home Depot, Inc. engages in the sale of building materials and home improvement products. Its products include building materials, home improvement products, lawn and garden products and décor products. The firm operates through the following geographical segments: U.S., Canada and Mexico. It offers home improvement installation services, and tool and rental equipment. The company was founded by Bernard Marcus, Arthur M. Blank, Kenneth Gerald Langone and Pat Farrah on June 29, 1978 and is headquartered at Atlanta, GA.

Home Depot, Inc.

Home Depot is drawing attention after a sharp pullback from a recent rebound, with traders debating whether buyers will defend support or the decline will deepen ahead of the companys earnings report. Bullish technical setups and call-option trades contrast with concerns about weak housing activity and interest-rate pressure; the discussion remains split.

CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

CVS Health Corp

CVS is drawing attention over reports that Aetnas 2027 Medicare Advantage star ratings have fallen, raising concern about lost quality bonuses and pressure on future margins. Traders debate whether the setback is already priced in, with some expecting a recovery while others point to the relative weakness versus insurers with improved ratings.

Dynex Capital, Inc. is an internally managed mortgage real estate investment trust. It engages in the business of investing in mortgage-backed securities. The company was founded on December 18, 1987 and is headquartered in Glen Allen, VA.

Dynex Capital, Inc.

Dynexs Q3 report is driving discussion after a sharp book-value decline attributed mainly to wider Agency MBS spreads, intensifying concerns about the share-price drop and dividend coverage. Some traders remain cautious, while others point to managements confidence in liquidity and future returns, along with recent insider purchases, as reasons to stay invested or add shares.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Should You Invest in the Vanguard Health Care Index Fund ETF Shares (VHT)?

Healthcare ETFs to Buy as JNJ Slips 6% Despite Q3 Earnings Beat 

Johnson & Johnson's Q3 earnings beat fails to prevent a 6% stock drop, but three healthcare ETFs offer diversified exposure to its growth potential. 

Healthcare ETFs to Buy as UnitedHealth Beats on Q3 Earnings

UnitedHealth's Q3 earnings beat estimates, lifting shares 6.3%. Explore three healthcare ETFs offering UNH exposure while diversifying Medicaid risks. 

Bet on These Healthcare ETFs to Benefit From the Aging US Population

With the US population aging rapidly, three healthcare ETFs offer exposure to companies developing treatments, drugs and medical devices for age-related conditions.

Better Healthcare ETF: Vanguard's Broad VHT vs. the iShares Biotechnology-Focused IBB

Key PointsThe Vanguard Health Care ETF offers a broad healthcare focus with a significantly lower expense ratio of 0.09% compared to its peer...

Consumer Sentiment Drops in September: ETFs to Consider

Consumer sentiment falls to a four-month low amid persistent inflation and uncertainty. Here are some ETFs that investors may consider.

MLTX Stock On Track For Worst Week Since Last Fall As FDA Filing Date For Skin Disease Drug Draws Near

Equity

MLTX has faded since a mid-June rally on year-long hidradenitis suppurativa data and an August psoriatic arthritis readout, leaving the stock more than 75% below its 52-week high.


Which Healthcare ETF Is the Better Buy: Vanguard's VHT or iShares' IXJ?

Key PointsThe Vanguard Health Care ETF (VHT) is significantly cheaper to own than the iShares Global Healthcare ETF (IXJ...

Vanguard Health Care ETF vs State Street XLV: Which ETF Is the Better Buy for Investors in 2026?

Key PointsVanguard Health Care ETF offers much broader diversification with 411 holdings compared to the 60 stocks in State Street Health Care Select Sector SPDR ETF...

Vanguard World Fund - Vanguard Health Care ETF

Bearish Sentiment

<ul class="summary-bullets"><li>MoonLake plans to file with the U.S. Food and Drug Administration (FDA) by the end of September, seeking permission to sell sonelokimab for hidradenitis suppurativa.&nbsp;</li><li>By late November, the FDA should say whether it accepted the filing, whether it will review it faster, and when it will decide.</li><li>Three shots are already approved for HS: AbbVie’s Humira, Novartis’s Cosentyx, and UCB’s Bimzelx.</li></ul><p>Shares of MoonLake Immunotherapeutics (MLTX) slid about 15% this week as investors marked down the stock weeks before a planned U.S. filing for its lead drug.</p><p>MLTX &nbsp;has faded since a mid-June rally on year-long hidradenitis suppurativa data and an August psoriatic arthritis readout, leaving the stock about 80% below its 52-week high. The stock is on track to clock its worst week in about a year, if losses hold.</p><h2 class="st-heading-2">Filing Date Looms</h2><p>MoonLake plans to file with the U.S. Food and Drug Administration (FDA) by the end of September, seeking permission to sell sonelokimab for hidradenitis suppurativa, a painful condition that causes boils and tunnels under the skin. The request would cover both adults and teens. The agency has already said the existing studies can support a filing.</p><p>By late November, the FDA should say whether it accepted the file, whether it will review it faster, and when it will decide. A standard review would point to a possible U.S. launch in the second half of 2027.</p><h2 class="st-heading-2">What The Drug Did In Trials</h2><p>Sonelokimab is an experimental injection that blocks two proteins that drive inflammation. After one year in two late-stage studies, about two-thirds of adults had a large drop in skin lesions and about one-third saw their lesions disappear. Early data in teens looked similar. Safety matched earlier studies.</p><p>Doubt remains because the first look at the data, at four months, was mixed. One study succeeded. The second missed its main goal after patients on dummy treatment improved more than expected, a setback that crushed the stock a year ago. The FDA, however, later said MoonLake did not need new skin-disease trials.</p><p>In August, a late-stage study of the drug in patients with psoriatic arthritis also hit its main goal.</p><h2 class="st-heading-2">A Crowded Market</h2><p>Three shots are already approved for HS: AbbVie’s Humira, Novartis’s Cosentyx, and UCB’s Bimzelx. Other new drugs are also in development.</p><p>MoonLake says its drug design and long-term trial results can help it stand out, but it would enter a market where rivals already have years of real-world use.</p><h2 class="st-heading-2">Next Catalysts</h2><p>MoonLake ended June with $537 million in cash, enough, it says, to last into mid-2028. It has no approved product and lost $131.5 million in the first half of 2026.</p><p>The nearest catalyst for the stock is the hidradenitis filing. A second late-stage joint-disease study should finish enrolling this quarter, with results later this year. MoonLake also plans to start a late-stage trial in palmoplantar pustulosis, which has no approved U.S. treatment.</p><h2 class="st-heading-2">How Did MLTX Retail Traders React?</h2><p>On Stocktwits, retail sentiment around MLTX stock stayed ‘neutral’ over the past 24 hours, while message volume was ‘high.’</p><p>A Stocktwits user said that shorts are resorting to bashing the company for its perceived lack of announcements, as they have no arguments against its drug.</p><p><stembedurl>https://stocktwits.com/Modern_portholio_theory/message/664081954</stembedurl></p><p>Another user opined that even with approval for sonelokimab, the company will enter a crowded market. “Yes the pie is big but it will &nbsp;be divided into many little pieces. $20 is already a lot for this company,” they wrote.</p><p><stembedurl>https://stocktwits.com/Antocar/message/664076232</stembedurl></p><p>Certain analysts, however, are more bullish. Last month, H.C. Wainwright raised the firm's price target on MoonLake Immunotherapeutics to $50 from $45 and kept a Buy rating on the shares after increasing its probabilities of approval to 70% from 60% in hidradenitis suppurativa, to 60% from 50% in psoriatic arthritis, and to 50% from 40% in axial spondyloarthritis.</p><p><a href="https://stocktwits.com/symbol/MLTX">MLTX stock</a> has fallen 3% year-to-date.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/dell-hpe-stocks-lead-s-and-p-500-gains-oracle-s-95-b-capex-plan-lifts-ai-stocks/cZtXFJxRBb2">DELL, HPE Stocks Lead S&amp;P 500 Gains: Oracle’s $95B Capex Plan Lifts AI Stocks</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the MoonLake Immunotherapeutics (Moon Lake) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

MLTX has faded since a mid-June rally on year-long hidradenitis suppurativa data and an August psoriatic arthritis readout, leaving the stock more than 75% below its 52-week high.

MoonLake Immunotherapeutics

T Rowe Price Capital Appreciation Equity ETF

Vanguard Health Care ETF

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$332.53
Prev Close	$336.26
Open	$334.36
Dividend Yield	N/A
50-Day Moving Average	$320.40
Beta	N/A
Avg. Volume	190,663.07
PE Ratio	N/A

52-Week High	$337.62
52-Week Low	$264.97
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

Feed

News

Sentiment

Fundamentals

Info

VHT Fundamentals